Moderna, Inc. (MRNA) Return on equity 2018–2025
Moderna, Inc. (MRNA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-32.6%FY2025 · since FY2018: -25.1% → -32.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -32.6% | +0.0 pp |
| FY2024 | -32.7% | +1.4 pp |
| FY2023 | -34.0% | -77.8 pp |
| FY2022 | 43.7% | -42.5 pp |
| FY2021 | 86.3% | +115.4 pp |
| FY2020 | -29.2% | +14.6 pp |
| FY2019 | -43.7% | -18.6 pp |
| FY2018 | -25.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice